Supply Chain

In today’s Pharma Pulse, Shionogi acquires global rights to the ALS treatment Radicava, and experts monitor drug supply chains as the U.S.-Iran conflict drives up logistics costs.

In today’s Pharma Pulse, Cold Chain Technologies sets a formal 2050 Net Zero goal to tackle the industry’s Scope 3 emissions, while a new Op/Ed highlights operational discipline as the vital driver for sustaining U.S. generic drug supplies.

CCT’s 2050 Net Zero goal will tackle Scope 3 emissions, which make up the majority of Pharma’s carbon footprint.

To fix America's drug shortages, pharma must look beyond manufacturing and overhaul how medicines are allocated and delivered to smaller hospitals.

Brightseed debuts a clinically validated AI platform to integrate life sciences innovation from discovery to commercialization

How the zero-prefix collision will disrupt reimbursement, patient access, brand protection and market intelligence — and what commercial leaders must do before 2033.

In today’s Pharma Pulse, industry leaders warn of serialization security issues and pharma companies brace for the 2033 NDC shift.

Matt Sample breaks down the operational hurdles and strategies for transitioning to the FDA’s new 12-digit NDC format.

Building climate-resilient cold chains with AI, smarter logistics, and collaboration to ensure safe delivery in a warming world.

Chronic shortages expose how low prices, fragile supply chains, and misaligned incentives are undermining the U.S. generic drug market.

In today's Pharma Pulse, the FDA approves Icotyde as the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis, while Cold Chain Technologies prepares to debut its MedAssure orchestration platform at LogiPharma 2026

Cold Chain Technologies will debut its MedAssure orchestration platform at LogiPharma 2026 providing a proactive solution for a cold chain market burdened by frequent temperature excursions.

In today's Pharma Pulse, ongoing conflict in the Middle East disrupts critical pharmaceutical cold chains, while AstraZeneca and partners launch a new program to decarbonize industrial heat across global supply chains.

Ongoing conflict in the Middle East has pushed pharmaceutical companies into cold chain rerouting scrambles.

AstraZeneca, ERM, and Secaro launched their Clean Heat Program to decarbonize supply chains.

Eli Lilly is investing $3 billion over the next decade to build a localized manufacturing and supply system in China.

The AI-native operating system targets complex workflows, automating claims and communications to reclaim logistics teams' time.

Even as manufacturers and their logistics partners grapple with unstable supply chains, the technology continues to evolve.

Rising geopolitical tensions in West Asia could threaten up to $600 million in Indian pharmaceutical exports.

A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity across manufacturer-to-home delivery networks, deploying AI to optimize operations, and adapting to evolving regulatory pressures shaping the future of healthcare supply chains.

From new formulations and vial formats to retailer expansion and pricing pressure, evolving GLP-1 strategies are transforming distribution models, reimbursement dynamics, and long-term supply planning.

The company is significantly lowering the US list prices for its popular weight loss and diabetes GLP-1 drugs, signaling a broader shift in pricing strategy as competition intensifies and access pressures grow.